Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $710.53 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Werfen USA LLC | $255.75 | 2 | $0 (2023) |
| Amgen Inc. | $154.83 | 2 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $124.29 | 1 | $0 (2017) |
| GRT US Holding, Inc. | $119.52 | 4 | $0 (2022) |
| Radius Health, Inc. | $35.00 | 1 | $0 (2019) |
| Meridian Bioscience Inc. | $21.14 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.83 | 1 | Amgen Inc. ($29.83) |
| 2023 | $255.75 | 2 | Werfen USA LLC ($255.75) |
| 2022 | $80.79 | 3 | GRT US Holding, Inc. ($59.65) |
| 2021 | $59.87 | 2 | GRT US Holding, Inc. ($59.87) |
| 2019 | $35.00 | 1 | Radius Health, Inc. ($35.00) |
| 2017 | $249.29 | 2 | Amgen Inc. ($125.00) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/08/2023 | Werfen USA LLC | — | Food and Beverage | Cash or cash equivalent | $83.10 | General |
| 08/11/2023 | Werfen USA LLC | — | Food and Beverage | Cash or cash equivalent | $172.65 | General |
| 08/24/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Pain Management | ||||||
| 04/28/2022 | Meridian Bioscience Inc. | — | Food and Beverage | Cash or cash equivalent | $21.14 | General |
| 01/18/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $32.26 | General |
| Category: Pain Management | ||||||
| 09/09/2021 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $30.27 | General |
| Category: Pain Management | ||||||
| 01/25/2021 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $29.60 | General |
| Category: Pain Management | ||||||
| 11/10/2019 | Radius Health, Inc. | Tymlos (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Endocrinology | ||||||
| 07/27/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $124.29 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/23/2017 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiology | ||||||
About Dr. Rubio Punzalan, M.D
Dr. Rubio Punzalan, M.D is a Anatomic Pathology & Clinical Pathology healthcare provider based in San Marino, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093937708.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rubio Punzalan, M.D has received a total of $710.53 in payments from pharmaceutical and medical device companies, with $29.83 received in 2024. These payments were reported across 11 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($710.53).
Practice Information
- Specialty Anatomic Pathology & Clinical Pathology
- Other Specialties General Practice
- Location San Marino, CA
- Active Since 05/03/2007
- Last Updated 12/09/2020
- Taxonomy Code 207ZP0102X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093937708
Products in Payments
- Repatha (Biological) $125.00
- ENTRESTO (Drug) $124.29
- Qutenza (Drug) $119.52
- Tymlos (Biological) $35.00
- KRYSTEXXA (Biological) $29.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.